Philadelphia chromosome-positive acute lymphoblastic leukemia in children: new and emerging treatment options.

@article{Schultz2010PhiladelphiaCA,
  title={Philadelphia chromosome-positive acute lymphoblastic leukemia in children: new and emerging treatment options.},
  author={Kirk R Schultz and Tim D. Prestidge and Bruce A. Camitta},
  journal={Expert review of hematology},
  year={2010},
  volume={3 6},
  pages={731-42}
}
Philadelphia chromosome-positive (Ph(+)) acute lymphoblastic leukemia (ALL) in children and adolescents has, until recently, been considered one of the poorest-risk subgroups of ALL. With chemotherapy alone, only 20-30% of children with Ph(+) ALL are cured. Allogeneic hematopoietic cell transplantation in first complete remission cures 60% of patients with a closely matched donor. Although targeted tyrosine kinase inhibitors (TKIs) have limited activity against Ph(+) ALL as a single agent, they… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 58 references

Progress in Ph+ ALL in children chromosome positive (Ph) acute lymphoblastic leukemia

P Rousselot, JM Cayuela, C Recher
Blood 116(12), • 2010

Switch pocket inhibitors of the ABL tyrosine kinase : distinct kinome inhibition profiles and in vivo efficacy in mouse models of CML and Blymphoblastic leukemia induced by BCR - ABL T 315 I

RA VanEtten, WA Chan, VM Zaleskas
Blood • 2010

Similar Papers

Loading similar papers…